|
1
|
Sanjida S, Betz-Stablein B, Atkinson V, Janda M, Barsoum R, Edwards HA, Chiu F, Tran MC, Soyer HP, Schaider H. In-Depth Characterisation of Real-World Advanced Melanoma Patients Receiving Immunotherapies and/or Targeted Therapies: A Case Series. Cancers (Basel) 2022; 14:cancers14112801. [PMID: 35681781 PMCID: PMC9179437 DOI: 10.3390/cancers14112801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 06/02/2022] [Indexed: 12/04/2022] Open
Abstract
Immunotherapies and targeted therapies have shown significant benefits for melanoma survival in the clinical trial setting. Much less is known about the characteristics and associated outcomes of those receiving such therapies in real-world settings. This study describes the characteristics of patients with advanced melanoma receiving immuno- and/or targeted therapies in a real-world setting. This prospective cohort study enrolled participants aged >18 years, diagnosed with advanced melanoma and currently undergoing immuno- and/or targeted therapies outside a clinical trial for follow-up with three-dimensional (3D) total-body imaging. Participants (n = 41) had a mean age of 62 years (range 29−86), 26 (63%) were male and the majority (n = 26, 63%) had ≥2 comorbidities. After a median of 39 months (range 1−52) follow-up, 59% (n = 24/41) of participants were alive. Despite multiple co-morbidities, the survival of participants with advanced melanoma treated using immuno- and/or targeted therapies was similar or better in our real-world setting compared to those treated in clinical trials using similar therapies. Larger studies powered to evaluate phenotypic and socio-economic characteristics, as well as specific comorbidities associated with survival in a real-world setting, are required to help determine those who will most benefit from immuno- and/or targeted therapies.
Collapse
Affiliation(s)
- Saira Sanjida
- Centre for Health Services Research, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD 4102, Australia; (S.S.); (M.J.)
- The University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia; (R.B.); (H.A.E.); (F.C.); (M.C.T.); (H.P.S.); (H.S.)
| | - Brigid Betz-Stablein
- The University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia; (R.B.); (H.A.E.); (F.C.); (M.C.T.); (H.P.S.); (H.S.)
- Correspondence: ; Tel.: +61-7-34437399
| | - Victoria Atkinson
- Cancer Care Services, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia;
| | - Monika Janda
- Centre for Health Services Research, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD 4102, Australia; (S.S.); (M.J.)
| | - Ramez Barsoum
- The University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia; (R.B.); (H.A.E.); (F.C.); (M.C.T.); (H.P.S.); (H.S.)
| | - Harrison Aljian Edwards
- The University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia; (R.B.); (H.A.E.); (F.C.); (M.C.T.); (H.P.S.); (H.S.)
| | - Frank Chiu
- The University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia; (R.B.); (H.A.E.); (F.C.); (M.C.T.); (H.P.S.); (H.S.)
| | - My Co Tran
- The University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia; (R.B.); (H.A.E.); (F.C.); (M.C.T.); (H.P.S.); (H.S.)
| | - H Peter Soyer
- The University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia; (R.B.); (H.A.E.); (F.C.); (M.C.T.); (H.P.S.); (H.S.)
- Dermatology Department, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia
| | - Helmut Schaider
- The University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Woolloongabba, QLD 4102, Australia; (R.B.); (H.A.E.); (F.C.); (M.C.T.); (H.P.S.); (H.S.)
- Dermatology Department, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia
| |
Collapse
|
|
2
|
Ferrari T, Lambertini M, Tartari F, Dika E. Melanoma and eruptive naevi during cetuximab treatment: epidermal growth factor inhibitors and a common concern. Clin Exp Dermatol 2021; 46:1584-1586. [PMID: 34080222 DOI: 10.1111/ced.14787] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/02/2021] [Indexed: 11/29/2022]
Affiliation(s)
- T Ferrari
- Division of Dermatology, IRCCS di Policlinico Sant'Orsola, Bologna, Italy
| | - M Lambertini
- Division of Dermatology, IRCCS di Policlinico Sant'Orsola, Bologna, Italy.,Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy
| | - F Tartari
- Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy
| | - E Dika
- Division of Dermatology, IRCCS di Policlinico Sant'Orsola, Bologna, Italy.,Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy
| |
Collapse
|
|
3
|
Dika E, Lambertini M, Gouveia B, Mussi M, Marcelli E, Campione E, Gurioli C, Melotti B, Alessandrini A, Ribero S. Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies. J Clin Med 2021; 10:jcm10061283. [PMID: 33808846 PMCID: PMC8003791 DOI: 10.3390/jcm10061283] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Revised: 03/12/2021] [Accepted: 03/15/2021] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen activated protein kinase) inhibitors, as well as immunotherapy against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1), have shown good results in improving the disease-free survival of patients with metastatic melanoma (MM). The aim of this review is to summarize the main oral adverse events (oAEs) occurring in patients undergoing target or immunotherapy. We proposed two separate sections: oAEs during the treatment with (1) target therapies with BRAF and MEK inhibitors and tyrosine kinase inhibitors (gingival hyperplasia, pigmentation disorders, squamo-proliferative lesions) and (2) immunotherapies with CTLA-4 or PD1 inhibitors (lichenoid reactions, immuno-bullous reactions, xerostomia and other reactions). Adverse events frequently include oAEs, although these are often misdiagnosed and under-reported. Indeed, the oral cavity is not routinely evaluated during clinical practice. The symptomatology related to oAEs is significant since it may represent the first manifestation of a severe systemic reaction, possibly leading to difficulties in nutrition with a consequent impact on patients' quality of life. A careful examination of the oral cavity is recommended during the evaluation of oncologic patients in order to promptly detect the onset of new manifestations.
Collapse
Affiliation(s)
- Emi Dika
- Division of Dermatology, IRCCS—Policlinico Sant’Orsola, via Massarenti 9, 40138 Bologna, Italy; (C.G.); (B.M.); (A.A.)
- Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy; (M.L.); (M.M.)
- Correspondence: ; Tel.: +39-0512144849
| | - Martina Lambertini
- Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy; (M.L.); (M.M.)
| | - Bruna Gouveia
- The Poche Centre, Melanoma Institute of Australia, 40 Rocklands Rd, Wollstonecraft, NSW 2065, Australia;
| | - Martina Mussi
- Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy; (M.L.); (M.M.)
| | - Emanuela Marcelli
- Laboratory of Bioengineering, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy;
| | - Elena Campione
- Dermatology Unit, University of Rome Tor Vergata, 00133 Roma, Italy;
| | - Carlotta Gurioli
- Division of Dermatology, IRCCS—Policlinico Sant’Orsola, via Massarenti 9, 40138 Bologna, Italy; (C.G.); (B.M.); (A.A.)
- Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy; (M.L.); (M.M.)
| | - Barbara Melotti
- Division of Dermatology, IRCCS—Policlinico Sant’Orsola, via Massarenti 9, 40138 Bologna, Italy; (C.G.); (B.M.); (A.A.)
| | - Aurora Alessandrini
- Division of Dermatology, IRCCS—Policlinico Sant’Orsola, via Massarenti 9, 40138 Bologna, Italy; (C.G.); (B.M.); (A.A.)
- Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy; (M.L.); (M.M.)
| | - Simone Ribero
- Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy;
| |
Collapse
|